IDXX vs NTLA
Idexx Laboratories Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | IDXX | NTLA |
|---|---|---|
| Revenue | $4.3B | $67.7M |
| Net income | $1.1B | $-412.7M |
| Gross margin | 61.8% | · |
| Net margin | 24.6% | −609.9% |
| Return on equity | 66.2% | −53.5% |
| Diluted EPS | $13.08 | −$3.81 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $1.1B | $-395.9M |
| Equity | $1.6B | $671.4M |
| Net debt / equity | 0.17× | · |
| Current ratio | 1.23× | 5.08× |
| Revenue CAGR 5y | 9.7% | 3.1% |
| Profit CAGR 5y | 12.7% | · |
IDXX bills 63.6× the revenue of NTLA, and NTLA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | IDXX | NTLA |
|---|---|---|
| FY2025 | $4.3B | $67.7M |
| FY2024 | $3.9B | $57.9M |
| FY2023 | $3.7B | $36.3M |
| FY2022 | $3.4B | $52.1M |
| FY2021 | $3.2B | $33.1M |
| FY2020 | $2.7B | $58.0M |
| FY2019 | $2.4B | $43.1M |
| FY2018 | $2.2B | $30.4M |
| FY2017 | $2.0B | $26.1M |
| FY2016 | $1.8B | $16.5M |
Bottom line
| Fiscal year | IDXX | NTLA |
|---|---|---|
| FY2025 | $1.1B | $-412.7M |
| FY2024 | $887.9M | $-519.0M |
| FY2023 | $845.0M | $-481.2M |
| FY2022 | $679.1M | $-474.2M |
| FY2021 | $744.8M | $-267.9M |
| FY2020 | $581.8M | $-134.2M |
| FY2019 | $427.7M | $-474.2M |
| FY2018 | $377.0M | $-85.3M |
| FY2017 | $263.1M | $-67.5M |
| FY2016 | $222.0M | $-31.6M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$4,236,031,000 | IDXX |
| FY2024 | +$3,839,627,000 | IDXX |
| FY2023 | +$3,624,678,000 | IDXX |
| FY2022 | +$3,315,203,000 | IDXX |
| FY2021 | +$3,182,307,000 | IDXX |
| FY2020 | +$2,648,661,000 | IDXX |
| FY2019 | +$2,363,805,000 | IDXX |
| FY2018 | +$2,182,808,000 | IDXX |
| FY2017 | +$1,942,941,000 | IDXX |
| FY2016 | +$1,758,944,000 | IDXX |
IDXX has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +634.5 pp | IDXX |
| FY2024 | +919.5 pp | IDXX |
| FY2023 | +1349.6 pp | IDXX |
| FY2022 | +929.9 pp | IDXX |
| FY2021 | +833.7 pp | IDXX |
| FY2020 | +253.0 pp | IDXX |
| FY2019 | +248.7 pp | IDXX |
| FY2018 | +297.5 pp | IDXX |
| FY2017 | +272.0 pp | IDXX |
| FY2016 | +204.5 pp | IDXX |
IDXX has kept the higher net margin in every one of these 10 fiscal years.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's net margin has been more volatile than IDXX's over the 10 comparable fiscal years — 375.1 percentage points of standard deviation against 4.0.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
IDXX led in net margin in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IDXX's return on equity has been more volatile than NTLA's over the 6 comparable fiscal years — 29.4 percentage points of standard deviation against 8.1.
6 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
IDXX led in return on equity in every one of the 6 comparable fiscal years — a structural lead, not a recent swing.
6 of 16 comparable fiscal years — a year missing data on either side is not counted.